The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193.
Philip Morris International
PM · a US exchange · USD · Market cap $301.0B · 84,900 employees
Philip Morris International Inc.
FAIL · Does not pass the screenPrice as of 17 Nov 2026Daily close, not a live quote
Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price194.38 USD at the 17 Nov 2026 close
- Our value readFair vs our fair value, as of 17 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.50)
- Last reviewed17 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $157.50 to $230.49, base estimate $200.42 (screen dated 2026-11-17).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.50, read 2026-11-13
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Philip Morris International holds its Distribution at $194.38. Consolidating, no directional conviction, held for 93 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 93 days |
| Price at the screen | $194.38 |
| Valuation | 28.19 trailing · 21.36 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 0.35 |
Five Screens, Shown in Full
Does not pass. Business activity screen
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Business activity: Tobacco | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Philip Morris International does not clear the screen at the business-activity stage. It operates in tobacco, so the financial ratios are not the deciding factor here.
Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PM's ethical verdict changes
Today PM does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 17 Nov 2026: it trades at roughly a 3% discount to our $200.42 fair value, 5.50% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 3.0% discount to the base estimate.
Third-party analyst targets: 15 covering, consensus Buy. The average target sits +13% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $200.42, with a range of $157.50 to $230.49, dated to the 2026-11-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsSmoking Through the Fog of Ethical Concerns
Imagine lighting up a cigarette, and with each puff, the smoke obscures not just your health but also your ethical vision. That's the conundrum Philip Morris International presents. As a global tobacco giant, it offers a smorgasbord of cigarettes and smoke-free alternatives under brands like IQOS and VEEV. Yet, the company's business activity flunks our ethical screen, a clear red flag in our books.
Despite a forward P/E of 20.9x and a 10% revenue growth, the numbers can't mask the ethical failings. Philip Morris sits at a profit margin of 26%, which might seem like a robust yield, but the market consensus is fragmented with no clear rating and a median target price of $210. The opportunity rating of AVOID is not due to a lack of financial performance, but the ethical smokescreen that surrounds it.
Risks are manifold, with the company's moat being unknown and the ethical failings a significant concern. The market may price it one way, but our ethical-first approach steers us clear from the smoke and mirrors of such businesses. Remember, when the ethical compass points away, it's often wise to follow. Analysis, not advice.
| Forward P/E | 21.4xexpensive even after accounting for its growth |
| Trailing P/E | 28.2xa premium valuation |
| EPS, trailing | 6.85 |
| EPS, forward | 9.04 |
| Revenue growth | +5.5%slow but positive growth |
| Profit margin | 24.8%healthy profit margins |
| FCF yield | 3.83% |
| Dividend yield | 3.11% |
| Current ratio | 1.02adequate liquidity, worth monitoring |
| Beta | 0.35barely tracks the market's swings |
| Short interest, float | 0.01% |
| 52-week range | 146.35 - 214.35 |
| Market cap | $301.0B |
| Employees | 84,900 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradePM trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- AIR Global Shipment Recovery Drives Double-Digit Growth – Quarterly Update Report Yahoo Finance · 1d ago
- Investing in Sin Stocks: Are These Overlooked Opportunities? Yahoo Finance · 2d ago
- Higher Rates Are Testing Philip Morris Stock and Other Dividend Defensives Yahoo Finance · 2d ago
- A $5.2 Billion Fund Dumps These 3 Stocks Yahoo Finance · 4d ago
- Altria or Philip Morris: Only One Gets My Dividend Dollars for the Next 10 Years Yahoo Finance · 5d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-06 | CALANTZOPOULOS ANDRE | Chairman of the Board | 1,119 | $190,152 | |
| 2026-05-06 | HARKER VICTORIA D | Director | 1,119 | $190,152 | |
| 2026-05-06 | GEISSLER WERNER | Director | 1,119 | $190,152 | |
| 2026-05-06 | HOOK LISA A. | Director | 1,119 | $190,152 | |
| 2026-05-06 | BOUGH BONIN | Director | 1,119 | $190,152 | |
| 2026-05-06 | COMBES MICHEL | Director | 1,119 | $190,152 | |
| 2026-05-06 | POLET ROBERT | Director | 1,119 | $190,152 | |
| 2026-05-06 | YANAI SHLOMO | Director | 1,119 | $190,152 | |
| 2026-05-06 | MORPARIA KALPANA | Director | 1,119 | $190,152 | |
| 2026-02-20 | DOBROWOLSKI REGINALDO | Officer | 6,000 | $1,100,880 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-10-15 | David Taylor | Republican | buy | 1K–15K |
| 2026-10-15 | David Taylor | Republican | buy | 1K–15K |
| 2026-10-15 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-10-15 | David Taylor | Republican | buy | 1K–15K |
| 2026-10-13 | Gil Cisneros | Democrat | sell | 50K–100K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $182.11 | +0.3% | · | $1,003 | +0.3% |
| 2 months | $160.45 | +13.9% | · | $1,139 | +13.9% |
| 3 months | $170.48 | +7.2% | $1.47 | $1,080 | +8.0% |
| 6 months | $148.26 | +23.2% | $2.94 | $1,252 | +25.2% |
| 1 year | $172.90 | +5.7% | $5.76 | $1,090 | +9.0% |
| 2 years | $95.83 | +90.7% | $11.11 | $2,023 | +102.3% |
| 3 years | $81.02 | +125.5% | $16.28 | $2,456 | +145.6% |
| 5 years | $77.95 | +134.4% | $26.29 | $2,681 | +168.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever PM does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.